Prelude Therapeutics Inc (PRLD)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.63+0.83%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Prelude Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	3.93M
EPS	—	-0.168
Annual ending 2026-12-31
Revenue	—	43.15M
EPS	—	-0.402
Annual ending 2027-12-31
Revenue	—	36.33M
EPS	—	-0.476

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS loss narrows toward -$0.94 in FY27	A supporting condition in Prelude Therapeutics Inc's published investment case. The stated target is EPS loss >= -$0.94.	Improving	EPS loss worsens beyond -$1.10 in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
File IND for PRT13722 by mid-2026	Prelude is on track to file IND for PRT13722 by mid-2026.	Intact	IND filing delayed beyond 2026-06-30	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth near 94% in FY26	A primary condition in Prelude Therapeutics Inc's published investment case. The stated target is >=94% YoY revenue growth.	Intact	revenue growth falls below 70% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 3
2026-07-25	Unavailable	Unavailable	2 / 3
2026-07-26	Unavailable	Unavailable	2 / 3
2026-07-27	Unavailable	Unavailable	1 / 2
2026-07-28	Unavailable	Unavailable	1 / 2
2026-07-29	Unavailable	Unavailable	1 / 2
2026-07-30	Unavailable	Unavailable	1 / 2
2026-07-31	Unavailable	Unavailable	1 / 2
2026-08-01	Unavailable	Unavailable	1 / 2
2026-08-02	Unavailable	Unavailable	1 / 2
2026-08-03	Unavailable	Unavailable	1 / 2
2026-08-04	Unavailable	Unavailable	1 / 2
2026-08-05	Unavailable	Unavailable	1 / 2
2026-08-06	Unavailable	Unavailable	1 / 2
2026-08-07	Unavailable	Unavailable	1 / 2
2026-08-08	Unavailable	Unavailable	1 / 2
2026-08-09	Unavailable	Unavailable	1 / 2
2026-08-10	Unavailable	Unavailable	1 / 2
2026-08-12	Unavailable	Unavailable	1 / 2
2026-08-13	Unavailable	Unavailable	1 / 2
2026-08-14	Unavailable	Unavailable	1 / 2
2026-08-15	Unavailable	Unavailable	1 / 2
2026-08-16	Unavailable	Unavailable	1 / 2
2026-08-17	Unavailable	Unavailable	1 / 2
2026-08-18	Unavailable	Unavailable	1 / 1
2026-08-19	Unavailable	Unavailable	1 / 2
2026-08-20	Unavailable	Unavailable	1 / 2
2026-08-21	Unavailable	Unavailable	1 / 2
2026-08-22	Unavailable	Unavailable	1 / 2
2026-08-23	Unavailable	Unavailable	1 / 2
2026-08-24	Unavailable	Unavailable	1 / 2
2026-08-25	Unavailable	Unavailable	1 / 2
2026-08-26	Unavailable	Unavailable	1 / 2
2026-08-27	Unavailable	Unavailable	1 / 2
2026-08-28	Unavailable	Unavailable	1 / 2
2026-08-29	Unavailable	Unavailable	1 / 2
2026-08-30	Unavailable	Unavailable	1 / 2
2026-08-31	Unavailable	Unavailable	1 / 2
2026-09-01	Unavailable	Unavailable	1 / 2
2026-09-02	Unavailable	Unavailable	1 / 2
2026-09-03	Unavailable	Unavailable	1 / 2
2026-09-04	Unavailable	Unavailable	1 / 2
2026-09-05	Unavailable	Unavailable	1 / 2
2026-09-06	Unavailable	Unavailable	1 / 2
2026-09-07	Unavailable	Unavailable	1 / 2
2026-09-08	Unavailable	Unavailable	1 / 2
2026-09-09	Unavailable	Unavailable	1 / 2
2026-09-10	Unavailable	Unavailable	1 / 2
2026-09-11	Unavailable	Unavailable	1 / 2
2026-09-12	Unavailable	Unavailable	1 / 2
2026-09-13	Unavailable	Unavailable	1 / 2
2026-09-14	Unavailable	Unavailable	1 / 2
2026-09-15	Unavailable	Unavailable	1 / 2
2026-09-16	Unavailable	Unavailable	1 / 2
2026-09-17	Unavailable	Unavailable	1 / 2
2026-09-18	Unavailable	Unavailable	1 / 2
2026-09-19	Unavailable	Unavailable	1 / 2
2026-09-20	Unavailable	Unavailable	2 / 2
2026-09-21	Unavailable	Unavailable	2 / 2
2026-09-22	Unavailable	Unavailable	2 / 2
2026-09-23	Unavailable	Unavailable	2 / 2
2026-09-24	Unavailable	Unavailable	2 / 2
2026-09-25	Unavailable	Unavailable	2 / 2
2026-09-26	Unavailable	Unavailable	2 / 2
2026-09-27	Unavailable	Unavailable	2 / 2
2026-09-28	Unavailable	Unavailable	2 / 2
2026-09-29	Unavailable	Unavailable	2 / 2
2026-09-30	Unavailable	Unavailable	2 / 2
2026-10-01	Unavailable	Unavailable	2 / 2
2026-10-02	Unavailable	Unavailable	2 / 2
2026-10-03	Unavailable	Unavailable	2 / 2
2026-10-04	Unavailable	Unavailable	2 / 2
2026-10-05	Unavailable	Unavailable	2 / 2
2026-10-06	Unavailable	Unavailable	2 / 2
2026-10-07	Unavailable	Unavailable	2 / 2
2026-10-08	Unavailable	Unavailable	2 / 2
2026-10-09	Unavailable	Unavailable	2 / 2
2026-10-10	Unavailable	Unavailable	2 / 2
2026-10-11	Unavailable	Unavailable	2 / 2
2026-10-12	Unavailable	Unavailable	2 / 2
2026-10-13	Unavailable	Unavailable	2 / 2
2026-10-14	Unavailable	Unavailable	3 / 2
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	0	0
2026-06-01	3	0	0
2026-07-01	3	0	0
2026-08-01	3	0	0
2026-09-01	5	0	0
2026-10-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS loss narrows toward -$0.94 in FY27Direct metric needs a verified mapping
File IND for PRT13722 by mid-2026Direct metric needs a verified mapping
Revenue growth near 94% in FY26Direct metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-70.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Prelude Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

PRLD is a speculative clinical-stage biotech, not a proven earnings compounder. Its long-term thesis is intact, with management on track to start a Phase 1 study for PRT13722 in Q4 2026 and extend cash runway into Q2 2028.

What's priced into Prelude Therapeutics Inc

The valuation model describes a durable premium versus peers, while the expectations gap is negative, suggesting expectations may be demanding relative to the model. The priced-in signal is tagged justified, with low fragility, but confidence is medium and the business remains loss-making.

What the fundamentals likely do

Near term, clinical progress and the planned Q4 trial start are supported by FDA clearance, and cash reserves rose to $155.2 million in Q2 2026. Recent results were described as holding in the top half of the industry, with earnings beats in May and August, though PRLD remains loss-making and has elevated risk. A potential guidance cut and weakening employment data are risks to watch.

What Prelude Therapeutics Inc hinges on

The multi-year view depends on whether PRT13722 enters Phase 1 as planned and PRT12396 continues to progress through its Phase 1 study. Near-term sentiment also depends on guidance and broader conditions: weaker jobs data could weigh on cyclical healthcare names, while continued strength from sector bellwethers could support the sector backdrop.